Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC

Season 9 Episode 22  ·  Aug 31, 2023, 08:55 PM

Headliner
Share
Subscribe

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

Share
Subscribe
Next
Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air